HLH has rarely been reported to occur following treatment with immune checkpoint inhibitors targeting PD-(L)1 and CTLA-4, is listed in the pembrolizumab FDA label, and in case reports, most patients recovered following immunosuppressive treatment (50, 63–65). This evidence concerns the gene CTLA4 and hemophagocytic syndrome.